Background. Two potencies of gelatin capsules containing Lactobacillus crispatus CTV-05 were evaluated for safety and vaginal colonization in 90 young women.
gram-negative rods, Gardnerella vaginalis, Mobiluncus species, other anaerobic gram-positive rods, and Mycoplasma hominis [3, 14] . Although the cure rate for BV with either metronidazole or clindamycin may initially be as high as 94% a week after treatment, studies consistently show recurrence, and the recurrence rate for BV may be Ͼ50% over a 12-month period [15] . Austin et al. [16] reported that H 2 O 2 -producing lactobacilli significantly increased after treatment, but only 48% of women were colonized by H 2 O 2 -producing lactobacilli 70 -90 days after metronidazole treatment (M. N. Austin, personal communication). Because H 2 O 2 -producing lactobacilli decrease the risk of BV and many women lack H 2 O 2 -producing lactobacilli after BV treatment, several researchers have proposed that introducing exogenous probiotic strains of lactobacilli could help restore normal vaginal microflora [17] [18] [19] .
Although strains of Lactobacillus fermentum and Lactobacillus rhamnosus have been extensively investigated as probiotics to help prevent urogenital infections [17, 18] , researchers recommend using Lactobacillus species commonly recovered from the vagina [20 -22] . Ge-nomic methods, including whole genomic characterization of vaginal microflora [14] , have documented that Lactobacillus crispatus is a predominant Lactobacillus species that vaginally colonizes women without BV-including pregnant women [20, 21] -in the United States [23] , Japan [24] , and Europe [20, 21, 25, 26] . Of women vaginally colonized by L. crispatus, an H 2 O 2 -producing species, 43% are also colonized rectally [23] . Compared with vaginal colonization alone, both vaginal and rectal colonization by H 2 O 2 -producing lactobacilli reduced the risk of BV 4-fold in a cross-sectional study [23] . The population-based prevalence of L. crispatus may be due to its superior capacity to persist in the vagina [27] . One strain, L. crispatus CTV-05, had a high mean adherence to vaginal epithelial cells in vitro [28] and established vaginal colonization in 7 of 9 women [19] .
The primary objective of the present double-blind, randomized single-center study was to evaluate the safety and colonization efficacy of 2 potencies of gelatin capsules containing L. crispatus CTV-05. The secondary objectives were to evaluate the effects of sexual activity and endogenous lactobacilli on vaginal colonization by probiotic lactobacilli.
METHODS
A double-blind, randomized study was conducted at the Adolescent Health Clinic at Children's Hospital of Pittsburgh and the Family Planning Clinic at Magee-Womens Hospital, Pittsburgh, Pennsylvania. Before enrollment, written informed consent was obtained from participants who were 18 years old and from guardians of participants who were 14 -17 years old. The participants were scheduled for follow-up visits at 7, 14, 21, and 28 days after enrollment, for a total of 5 visits. The study population comprised 90 sexually active, nonpregnant female subjects who were 14 -21 years of age and free of genital infections. Subjects were excluded from enrollment if they were positive for BV, candidiasis, trichomoniasis, or cervicitis or if they had colposcopic abnormalities of the vulva, vagina, or cervix. In the conduct of clinical research, the human-experimentation guidelines of the US Department of Health and Human Services were followed.
The 90 participants were randomized with equal frequency to the 2 intervention groups, using a permuted block design with a block size of 4. One group received gelatin capsules containing 10 6 cfu of L. crispatus CTV-05 in a desiccated state, and the other group received identical capsules containing 10 8 cfu of L. crispatus CTV-05. All capsules were packaged identically and were indistinguishable in appearance. Both study staff and participants were masked as to the allocation group.
Participants were given detailed verbal instructions for digital insertion of the vaginal capsules and were directed to avoid using intravaginal products, including douches and medications, during the 48 h preceding a follow-up visit. During the enrollment visit, 1 vaginal capsule was inserted by the participant under the supervision of a study clinician. Participants were given 5 additional envelopes, each containing 1 vaginal gelatin capsule. They were instructed to insert 1 gelatin capsule on the evening of the enrollment visit, at least 6 h after the insertion of the first capsule, and to insert the remaining capsules twice a day for the next 2 days.
All visits included a speculum examination of the cervix and vaginal walls and an inspection of the external genitalia for erythema, edema, and lesions. Participants also underwent colposcopic examinations during enrollment and at the 7-day follow-up visit. The vulva, vagina, and cervix were evaluated for erythema, epithelial disruption, and sloughing. One nurse practitioner conducted all of the colposcopic examinations.
At each visit, participants were interviewed using a standardized questionnaire to obtain demographic, behavioral, and medical information, which included urethral, external genitalia, vaginal, and abdominal symptoms. The participants were asked to complete daily diaries for the 14 days after enrollment. The diaries involved circling "yes" or "no" for a list of symptoms and writing short answers about intercourse, medication, vaginal products, and general wellness.
At enrollment and at subsequent visits when clinically indicated, cervical specimens were obtained for Neisseria gonorrhoeae culture and Chlamydia trachomatis nucleic acid amplification testing. A vaginal swab sample was collected to inoculate modified Diamond's medium for Trichomonas vaginalis. A suspension made from a vaginal swab placed into sterile saline was examined under high power (ϫ400) for the presence of clue cells, motile trichomonads, and yeast. Vaginal fluid was tested for amine odor and vaginal pH.
For all visits, a vaginal swab sample was rolled onto a slide that was Gram stained and scored for BV using the Nugent criteria [29] . Additionally, 2 Dacron swabs were used to obtain samplings from the lateral vaginal wall and placed into an anaerobic transport gel contained in a BBL Port-A-Cul tube (Becton Dickinson). The sample was delivered to the research laboratory within 12 h for quantitative culture set up for the detection of microorganisms, as described elsewhere [16] .
To differentiate L. crispatus CTV-05 from other lactobacilli and other L. crispatus strains, repetitive-sequence polymerase chain reaction (rep-PCR) DNA fingerprinting was performed, as described elsewhere [19] . A total of 1670 Lactobacillus isolates from 436 visits were recovered by culture and subjected to rep-PCR. A mean of 3.8 Lactobacillus isolates were evaluated per visit.
Species-level identification of lactobacilli was performed using DNA hybridization, as described elsewhere [23] . If Ͼ2 isolates from the same participant had similar rep-PCR DNA fingerprints (i.e., were the same strains), only 1 was identified to the species level. Of the 246 lactobacilli isolated from the enrollment visits, 146 isolates were subjected to species-level identification.
Fisher's exact test was used to compare enrollment characteristics between the randomization arms, colonization efficacy according to the potency of CTV-05 capsules, and colonization efficacy according to the presence or absence of endogenous Lactobacillus species at enrollment. Colonization was defined as the presence of the CTV-05 strain at a follow-up visit. Changes in the prevalence of vaginal microorganisms within each potency group over the 5 visits were evaluated using Cochran's Q test for several related samples. Changes in the median log concentrations of vaginal microflora within each potency group over the 5 visits were evaluated using Friedman's test; participants who were negative for the presence of a specific microorganism were included. Median concentrations of H 2 O 2 -producing lactobacilli at the 7-day follow-up visit for participants who were never colonized with CTV-05 were compared with concentrations at the first-colonizing visit for participants who were colonized with CTV-05 by the Mann-Whitney U test. Logistic regression models were used to identify factors associated with noncolonization with L. crispatus CTV-05 at any follow-up visit. Models were developed using forward stepwise regression, and variables were retained if the Wald 2 test statistic yielded P р .05.
RESULTS
The demographic and behavioral characteristics of the 90 enrolled participants are shown in table 1. There were no differences in these characteristics between the 2 randomization groups. Although all participants reported previous sexual activity, only 58 (64%) reported vaginal intercourse in the month before enrollment. None of the participants reported having female sex partners. Of the 90 enrolled participants, 3 did not return for any follow-up visits. The resulting modified intention-to-treat data set of 87 females includes 8 participants with 1 visit out of window and 1 participant who did not return for her 21-and 28-day follow-up visits. Of 450 potential study visits for the trial, 436 (97%) were completed.
No statistically significant difference was found between the 2 potency groups with respect to vaginal colonization by L. crispatus CTV-05 at each individual visit or overall colonization, suggesting that the 2 capsules were similarly efficacious at establishing colonization. Overall, CTV-05 was recovered at 1 follow-up visit or more for 60 (69%) of the 87 participants. Of the 86 participants who completed all visits, 51 (59%) were positive for CTV-05 colonization at the 28-day visit. Of these 51 participants, 38 sustained colonization of CTV-05 from the 7-day visit, 8 from the 14-day visit, and 2 from the 21-day visit. CTV-05 was first detected at the 28-day visit for 3 participants. For 8 of the 86 participants, CTV-05 was detectable at a single follow-up visit, but colonization was not sustained.
Because endogenous Lactobacillus species could competitively inhibit colonization by the probiotic L. crispatus CTV-05, the vaginal Lactobacillus species colonizing the participants at enrollment were evaluated as a predictor of CTV-05 colonization at follow-up. At enrollment, only 9 (10%) of the 87 subjects were lacking lactobacilli, 34 (39%) were colonized by 1 Lactobacillus species, and 44 (51%) were colonized by Ͼ1 Lactobacillus species. The most prevalent vaginal Lactobacillus species at enrollment was L. crispatus, which colonized more than half (54%) of the 87 participants, followed by L. iners (43%), L. jensenii (28%), and L. gasseri (20%) ( To determine whether CTV-05 colonization was sustained throughout the 5 weeks of follow-up, CTV-05 colonization frequency was compared among participants who were colonized by L. crispatus at enrollment and participants who lacked endogenous L. crispatus before capsule use (figure 1). CTV-05 was detected at the first follow-up visit in 83% of the participants who lacked L. crispatus colonization at enrollment, compared with only 28% of those who had L. crispatus colonization at enrollment. Colonization by CTV-05 was sustained at the 14-, 21-, and 28-day follow-up visits in a higher proportion of females initially lacking L. crispatus colonization, compared with the females colonized by endogenous L. crispatus. The modest increase in CTV-05 detection at the 21-and 28-day visits was due to the increased detection of CTV-05 in participants who had L. crispatus colonization at enrollment.
Multivariable analysis also showed that participants already vaginally colonized by L. crispatus before the introduction of probiotic L. crispatus CTV-05 were significantly less likely to be colonized by the exogenous strain (table 3) . Additional factors associated with failure to be colonized by CTV-05 included sexual intercourse with the use of condoms for contraception or unprotected sexual intercourse during the week the vaginal capsules were used (table 3) . Participants who remained sexually abstinent for the first 14 days after enrollment were the most likely to be colonized by CTV-05, compared with participants who had sexual intercourse with the use of condoms for contraception or unprotected sexual intercourse during the week of capsule use. No other factors were found to be associated with noncolonization, including race, age, potency, and vaginal pH at enrollment.
To evaluate whether colonization by the capsule strain resulted in higher-density Lactobacillus colonization, total coloni-zation density at enrollment was compared with that at the first visit when CTV-05 was detected. Of the 60 participants colonized by CTV-05 during the study, 42 were colonized at enrollment by H 2 O 2 -producing lactobacilli, at a median concentration of 10 7.4 cfu/mL of vaginal fluid (range, 10 3.1 -10 8.8 ). By comparison, the median concentration of H 2 O 2 -producing lactobacilli at the first visit when CTV-05 was detected was 10 7.5 cfu/mL of vaginal fluid (range, 10 3.1 -10 8.9 ). CTV-05 was not detected at any visit for 27 participants (31%). For this group, the median concentration of H 2 O 2 -producing lactobacilli was 10 7.8 cfu/mL of vaginal fluid (range, 10 3.0 -10 8.5 ) at enrollment and 10 7.5 cfu/mL of vaginal fluid (range, 10 5.1 -10 8.6 ) at the first follow-up visit among the participants colonized by these microorganisms. Thus, there was no significant difference in the median concentration of H 2 O 2 -producing lactobacilli between participants colonized with CTV-05 at any visit and participants who were never colonized (P ϭ .508).
Another measure of safety was the analysis of vaginal microflora before and after capsule use. Across the follow-up period, there were no significant changes in prevalence or median log concentration for anaerobic gram-negative rods, Prevotella bivia, black-pigmented anaerobic gram-negative rods, G. vaginalis, anaerobic gram-positive cocci, group B Streptococcus, Escherichia coli, and any yeast. There was, however, a significant increase in the prevalence of H 2 O 2 -producing lactobacilli in both potency groups. The proportion of females with colonization by H 2 O 2 -producing lactobacilli increased from 69% at enrollment to 93% at the 7-day follow-up visit in the group receiving 10 6 -cfu capsules. At enrollment, a higher proportion (83%) of participants in the 10 8 -cfu potency group had H 2 O 2 -producing lactobacilli colonization, and this proportion increased to 100% by the 7-day follow-up visit. The frequency of colonization by H 2 O 2 -producing lactobacilli was higher at the 28-day follow-up visit than at the enrollment visit for both potency groups.
The colposcopic examinations at enrollment and the 7-day follow-up visit, the weekly pelvic examinations, and the symptom reviews from diaries and interviews from a total of 436 patient visits were important for assessing physiologic safety and revealed 47 adverse events. None of the adverse events were severe enough to prompt a participant to contact a study clinician before a scheduled research visit. The 47 adverse events recorded occurred in 32 (37%) of 87 participants. Of the 47 adverse events, 22 were coded by the study clinician as being unrelated to capsule use. For the remaining 25 events coded as being possibly related or having an unknown relationship to L. crispatus capsule use, 5 had no physical findings or symptoms; 17 were of mild severity, including pruritis (n ϭ 3), BV (n ϭ 2), urinary symptoms (n ϭ 2), yeast vaginitis (n ϭ 3), menstrual pain (n ϭ 1), retained condom (n ϭ 1), and other varied but minor events (n ϭ 5); and 3 were moderately severe and required antifungal therapy for yeast vaginitis. None of the adverse events were severe enough that the participant had to be removed from the study.
Vaginal discharge was the only symptom whose frequency increased significantly, to a maximum of 74% during the second day of capsule use. The frequency of discharge returned to levels reported at enrollment by day 5, and discharge was reported in only 18% of the subjects by the end of the study. The temporal association between capsule use and the symptoms of discharge suggested that discharge resulted from the dissolution of the capsule, not a physiologic source. Unprotected vaginal intercourse during the days surrounding capsule use also substantially decreased the likelihood of successful colonization. The high pH of seminal fluid may affect the adherence or survivability of CTV-05. Alternatively, a component of seminal fluid may block the adherence of CTV-05 to vaginal epithelial cells. It is also possible that CTV-05 is adherent to and is transferred by sperm [30] . Sexual intercourse with the use of condoms also affects colonization, although less significantly than unprotected sex. In one study, the levels of vaginal lactobacilli already colonizing the vagina 1-2 days before sexual intercourse with or without a condom were not significantly affected 8 -12 h after intercourse [31] . Therefore, every effort should be made to instruct women to remain abstinent during actual capsule use and for at least 11 days after the first capsule, which should allow sufficient time for CTV-05 to adhere to vaginal epithelial cells. The lack of colonization among women having unprotected sex may be a serious limitation of the probiotic approach.
DISCUSSION
Ninety percent of the enrolled young women were vaginally colonized by lactobacilli before using the L. crispatus CTV-05 capsules, and 76% were vaginally colonized by H 2 O 2 -producing strains. This was not surprising given that all females with BV and other genital tract infections were excluded. L. iners, a non-H 2 O 2 -producing species, had an unexpectedly higher prevalence and frequency of cocolonization with other Lactobacillus species than reported elsewhere for cultivated lactobacilli from the vagina [23] .
The high prevalence of endogenous lactobacilli before capsule use minimized the "net increase" in Lactobacillus colonization that was theoretically possible in this trial. One possible safety concern regarded the potential for Lactobacillus "overgrowth" with multiple doses of exogenous lactobacilli. Twice-daily insertion of the vaginal capsules for 3 days did not amplify the vaginal Lactobacillus population, which remained relatively constant, suggesting that the exogenous strain of L. crispatus adjusted to normal physiologic levels (10 7 -10 8 cfu/mL of vaginal fluid) and remained at these levels throughout the follow-up period. The failure to successfully colonize women who already have optimal levels of L. crispatus should not be seen as a shortcoming of this product, but rather as a self-regulatory mechanism within the vaginal ecosystem.
A 3-day twice-daily dose of 10 6 or 10 8 cfu of L. crispatus CTV-05 is sufficient to establish lactobacilli colonization in women lacking Lactobacillus. Other studies using DNA fingerprinting methods found that a 3-day daily vaginal capsule dose of 10 9 cfu (total) of L. rhamnosus GR-1 and L. fermentum RC-14 or 10 10 cfu of L. rhamnosus GG resulted in low frequencies of colonization by the microorganisms by day 21 [18, 32] . In contrast, CTV-05 was detected in more than half (58%) of the participants in this study at the 21-day visit, suggesting that a Lactobacillus species that is predominantly found in the vagina may be a more successful vaginal probiotic than L. rhamnosus and L. fermentum, which are not prevalent in the vagina.
A limitation of this study is the reliance on visual detection of the probiotic strain by culture. The colony morphology of the probiotic strain and that of endogenous L. crispatus may be very similar and difficult to discern. During the early follow-up visits, CTV-05 may be present in very low quantities and masked by other bacteria. Aside from fingerprinting strain-typing methods, there are no direct detection genetic methods to identify the CTV-05 strain. A second limitation was the reliance on selfreport to assess participants' adherence to product use. Finally, results may not be generalizable to adult women or women with vaginal infections, because only females 14 -21 years old without genital infections were included in the study. The purpose of the present study was to better characterize the safety of L. crispatus CTV-05 capsules inserted intravaginally. The only event recorded in the diaries that was temporally associated with use of the vaginal Lactobacillus capsule was vaginal discharge, which was also frequently reported in a study of CTV-05 for women with recurrent urinary tract infection [33] . The sensation of discharge was most likely attributable to the melting of the capsule, given that gelatin melts at body temperature in the presence of genital fluid. The dissolution of the capsule may result in increased discharge, but no significant adverse effects were attributable to capsule use.
L. crispatus CTV-05 effectively colonized the vagina of 90% of women lacking endogenous L. crispatus but successfully colonized only half of women already colonized by L. crispatus at enrollment. Lengthening the 3-day dosing period evaluated in this study may increase colonization by the probiotic strain. Additional studies of the product will be needed to assess whether vaginal capsules containing L. crispatus CTV-05 will be a useful adjunct to antibiotic treatment for the prevention of recurrent BV.
